Literature DB >> 22362258

Tc-99m diethylenetriamine pentaacetic acid (DTPA) renal function reserve estimation: is it a reliable predictive tool for assessment of preclinical renal involvement in scleroderma patients?

Amr Amin1, S El-Sayed, N Taher, M Sedki, H Nasr.   

Abstract

Prognosis of systemic sclerosis (SSc) depends on internal organ involvement. We assessed the value of renal function reserve (RFR) for the detection of preclinical nephropathy in scleroderma. Thirty SSc patients with normal serum creatinine and 30 healthy controls were included. Medsger disease severity score, glomerular filtration rate (GFR), and microalbuminuria were measured. Tc-99m DTPA was utilized for GFR measurement at baseline and after oral protein overload (stimulated GFR). RFR was calculated as the percentile increase of stimulated GFR. SSc patients had lower means of baseline GFR (P=0.001), stimulated GFR (P=0.004), RFR (P=0.046), and higher microalbuminuria (P=0.009) than controls. According to baseline GFR, SSc patients showed three categories-normal baseline GFR (n=12), hyperfiltration GFR (n=3), and reduced baseline GFR (n=15). In the former category, RFR was normal in 6/12 patients and abnormal in the remainders (50%). Hyperfiltration patients and those with reduced baseline GFR showed abnormal RFR. A statistically significant negative association was found between microalbuminuria versus stimulated GFR and RFR (r= -0.5, P=0.007 and r= -0.45, P=0.013, respectively). The majority of SSc patients with abnormal RFR had disease duration of ≥48 months (60% vs. 20%, P=0.008). All SSc patients with pulmonary hypertension had abnormal RFR, while reduced baseline GFR was noted in only 60%. A significant negative correlation was found between reduced baseline GFR and cumulative dose of corticosteroids in SSc patients (r= -0.4, P=0.022). RFR estimation could be a useful predictive marker for preclinical renal involvement in SSc patients so that early prophylactic measures and therapy modifications could be considered.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22362258     DOI: 10.1007/s10067-012-1963-y

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  40 in total

1.  Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension.

Authors:  Aránzazu Campo; Stephen C Mathai; Jérôme Le Pavec; Ari L Zaiman; Laura K Hummers; Danielle Boyce; Traci Housten; Hunter C Champion; Noah Lechtzin; Fredrick M Wigley; Reda E Girgis; Paul M Hassoun
Journal:  Am J Respir Crit Care Med       Date:  2010-03-25       Impact factor: 21.405

2.  Renal vascular damage in systemic sclerosis patients without clinical evidence of nephropathy.

Authors:  R Rivolta; B Mascagni; V Berruti; F Quarto Di Palo; A Elli; R Scorza; D Castagnone
Journal:  Arthritis Rheum       Date:  1996-06

3.  Microalbuminuria in systemic sclerosis.

Authors:  A Dawnay; A G Wilson; E Lamb; J D Kirby; W R Cattell
Journal:  Ann Rheum Dis       Date:  1992-03       Impact factor: 19.103

4.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.

Authors: 
Journal:  Arthritis Rheum       Date:  1980-05

5.  Renal manifestations in scleroderma: evidence for subclinical renal disease as a marker of vasculopathy.

Authors:  Victoria K Shanmugam; Virginia D Steen
Journal:  Int J Rheumatol       Date:  2010-08-17

Review 6.  Renal functional reserve in subjects with diabetes mellitus.

Authors:  S L Jones; G Viberti
Journal:  Semin Nephrol       Date:  1995-09       Impact factor: 5.299

7.  Intermediate molecular weight proteinuria and albuminuria identify scleroderma patients with increased morbidity.

Authors:  B Seiberlich; N Hunzelmann; T Krieg; M Weber; E Schulze-Lohoff
Journal:  Clin Nephrol       Date:  2008-08       Impact factor: 0.975

8.  Calculated glomerular filtration rate is a useful screening tool to identify scleroderma patients with renal impairment.

Authors:  E J Kingdon; C J Knight; K Dustan; A G Irwin; M Thomas; S H Powis; A Burns; A J W Hilson; C M Black
Journal:  Rheumatology (Oxford)       Date:  2003-01       Impact factor: 7.580

9.  Scleroderma renal crisis: patient characteristics and long-term outcomes.

Authors:  H Penn; A J Howie; E J Kingdon; C C Bunn; R J Stratton; C M Black; A Burns; C P Denton
Journal:  QJM       Date:  2007-06-29

10.  Prevalence of renal involvement in Indian patients with systemic sclerosis.

Authors:  R Gupta; C Bammigatti; A K Dinda; V Marwaha; S Gupta
Journal:  Indian J Med Sci       Date:  2007-02
View more
  5 in total

Review 1.  Recent Developments in the Classification, Evaluation, Pathophysiology, and Management of Scleroderma Renal Crisis.

Authors:  Cybele Ghossein; John Varga; Andrew Z Fenves
Journal:  Curr Rheumatol Rep       Date:  2016-01       Impact factor: 4.592

Review 2.  Scleroderma renal crisis and renal involvement in systemic sclerosis.

Authors:  Thasia G Woodworth; Yossra A Suliman; Wendi Li; Daniel E Furst; Philip Clements
Journal:  Nat Rev Nephrol       Date:  2016-09-19       Impact factor: 28.314

Review 3.  Kidney involvement in systemic sclerosis: From pathogenesis to treatment.

Authors:  Cosimo Bruni; Giovanna Cuomo; Francesca W Rossi; Emanuela Praino; Silvia Bellando-Randone
Journal:  J Scleroderma Relat Disord       Date:  2018-04-04

4.  A comparison between 2017 FAS and 2012 CKD-EPI equations: a multi-center validation study in Chinese adult population.

Authors:  Zhenzhu Yong; Fen Li; Xiaohua Pei; Xun Liu; Dan Song; Xiaoxuan Zhang; Weihong Zhao
Journal:  Int Urol Nephrol       Date:  2018-10-24       Impact factor: 2.370

5.  Influence of antiphospholipid antibody positivity on glomerular filtration rate markers in a group of systemic sclerosis patients - a 24-month observation.

Authors:  Ewa Wielosz; Maria Majdan; Arkadiusz Koszarny; Magdalena Dryglewska; Jacek Tabarkiewicz
Journal:  Cent Eur J Immunol       Date:  2017-08-08       Impact factor: 2.085

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.